September 12, 2016
EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif., last month. Mylan said it will make available a generic version of its EpiPen, as criticism mounts over the price of its injectable medicine.
(Photo:
Rich Pedroncelli/AP)
The company made changes in its anti-allergy EpiPen dispenser in 2009, enough to give it patent protection. Then, in 2012, it began to give away free pens to schools, gradually making school nurses at least partly dependent on them.
Meanwhile the company was successfully lobbying for the "Emergency Epinephrine Act," commonly referred to as the "EpiPen Law," which encouraged the presence of epinephrine dispensers in schools.
Most recently,
after raising the price from $100 to $600, Mylan
announced a
half-price coupon,
making itself appear generous even though the price had effectively
jumped from $100 to $300.
These are the sins of
the pharmaceutical industry.
An American with cancer will face bills up to $183,000 per year, even though it hasn't been established that the expensive treatments actually extend lives.
A 12-week course of Sovaldi, for hepatitis, costs Gilead Sciences about $84 and is priced at $84,000. This is an industry that can suddenly impose a 60,000% increase on desperately ill people.
Yet
the pharmaceutical industry's profit margin is matched only by the
unscrupulous
financial industry for the highest corporate profit margin.
A recent Health Affairs study concluded that since 2004 our medical dollars have been,
As a result the richest 1% of American males live nearly 15 years longer than the poorest 1% (10 years for women).
The
high cost of medication is one of the factors leading to early
death.
The average medical insurance
deductible has increased
67 percent since 2010, and most Medicare patients still face
out-of-pocket costs of $7,000 or more a year.
Pharmaceutical lobbyists have rigged the system to
prevent Medicare from
negotiating for lower drug prices.
An example is genetically engineered insulin, which due to patent protection cannot be made generically, and as a result can cost a patient up to $5,000 a year, many times more than a patent-expired version.
Another example is the anti-parasite
drug
Daraprim, which has been on the market for 62 years, yet was
appropriated by the now-infamous Martin Shkreli and price-hiked from
$13.50 to $750.00.
Meanwhile, Big Pharma has
cut nearly 150,000 jobs since 2008, mostly in R&D.
Adding a further touch of hypocrisy, Mylan sought
U.S. government
help when another company tried to buy it out.
|